Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
Zacks News
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.
Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.
CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.
Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised
by Zacks Equity Research
Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.